Report - Novartis AG Investor Relations...Fluid is a critical marker for treatment and switching decisions For ~90% of survey participants fluid on OCT is THE major driver of re-treatment in

Select PornographicDefamatoryIllegal/UnlawfulSpamOther Terms Of Service ViolationFile a copyright complaint

Please pass captcha verification before submit form